Aktie A016790 CANARIABIO INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen CANARIABIO Inc.

Aktien

A016790

KR7016790008

A016790

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 29.02.2024 		% 5 Tage % 1. Jan.
994 KRW +8.52% Intraday Chart für CANARIABIO Inc. -.--% -80.70%
2023 Specialised Therapeutics Asia Pte Ltd unterzeichnet exklusive Lizenzvereinbarung mit CanariaBio für neue Eierstockkrebs-Therapie CI
2023 CanariaBio Inc. CanariaBio Inc. gibt den Abschluss der Rekrutierung für eine Phase-2-Studie mit Oregovomab in Kombination mit Niraparib zur Behandlung von rezidivierendem Eierstockkrebs bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CANARIABIO Inc.(KOSDAQ:A016790) dropped from S&P Global BMI Index
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis
CANARIABIO Inc. announced that it has received KRW 4.999995308 billion in funding from CANARIABIO M Inc.
CANARIABIO Inc. announced that it expects to receive KRW 4.999995308 billion in funding from CANARIABIO M Inc.
Specialised Therapeutics Asia Pte Ltd Signs Exclusive License Agreement with CanariaBio for New Ovarian Cancer Therapy
Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa
CanariaBio Inc. Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer
CANARIABIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
An Unknown buyer agreed to acquire 2.133768% stake in CANARIABIO Inc. from CANARIABIO M Inc. for KRW 14 billion.
CANARIABIO Inc. announced that it has received KRW 15 billion in funding from AT semicon Co., Ltd.
CANARIABIO Inc. announced that it has received KRW 10 billion in funding from AT semicon Co., Ltd.
CANARIABIO Inc. announced that it has received KRW 10 billion in funding from CANARIABIO Inc.
CANARIABIO Inc. announced that it has received KRW 30 billion in funding from CANARIABIO M Inc.
CANARIABIO Inc. announced that it has received KRW 20 billion in funding from CANARIABIO M Inc.
CANARIABIO Inc. announced that it expects to receive KRW 20 billion in funding from CANARIABIO M Inc.
CANARIABIO Inc. announced that it expects to receive KRW 30 billion in funding from CANARIABIO M Inc.
CANARIABIO Inc. announced that it has received KRW 80 billion in funding from CANARIABIO M Inc.
CANARIABIO Inc. announced that it has received KRW 29.999997555 billion in funding from Sejong Medical Co., Ltd.
CANARIABIO Inc. announced that it expects to receive KRW 19.99999837 billion in funding from Sejong Medical Co., Ltd.
CANARIABIO Inc.(KOSDAQ:A016790) added to S&P Global BMI Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A016790 Aktie
  4. Nachrichten CANARIABIO Inc.
  5. Andere Sprachen